Recombinant Human Fas Ligand Protein (N-6His)

Name: Recombinant Human Fas Ligand Protein (N-6His)
Brand: Beta LifeScience
SKU: BL-2091NP
Availability: InStock

BL-2091NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, Buy cytokines, chemokines, and growth factors for research online, High-quality recombinant proteins, Other cytokines

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Tumor Necrosis Factor Ligand Superfamily Member 6 is produced by our Mammalian expression system and the target gene encoding Pro134-Leu281 is expressed with a 6His tag at the N-terminus.
Accession	P48023
Synonym	apoptosis (APO-1) antigen ligand 1; Apoptosis antigen ligand; APT1LG1CD95L; APTL; CD178 antigen; CD178; CD95L; CD95-L; Fas antigen ligand; Fas ligand (TNF superfamily, member 6); Fas Ligand; FASLCD95 ligand; FASLG; TNFSF6
Gene Background	Fas ligand is also known as FasL, CD178, CD95L, or TNFSF6, is a homotrimeric type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its ability to induce apoptosis in target cells plays an important role in the development, homeostasis, and function of the immune system. Interaction of FAS with fas Ligand is critical in triggering apoptosis of some types of cells such as lymphocytes. Fas Ligand may be involved in cytotoxic T-cell mediated apoptosis and in T-cell development. TNFRSF6/FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both.
Molecular Mass	17.7 KDa
Apmol Mass	20-30 KDa, reducing conditions
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Biologically active. Please contact us to obtain bioactivity data.
Reconstitution
Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis.; Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways. Can induce apoptosis but does not appear to be essential for this process.; Cytoplasmic form induces gene transcription inhibition.
Subcellular Location	Cell membrane; Single-pass type II membrane protein. Cytoplasmic vesicle lumen. Lysosome lumen.; [Tumor necrosis factor ligand superfamily member 6, soluble form]: Secreted.; [FasL intracellular domain]: Nucleus.
Protein Families	Tumor necrosis factor family
Database References	HGNC: 11936 OMIM: 134638 KEGG: hsa:356 STRING: 9606.ENSP00000356694 UniGene: PMID: 29611722 Evaluation of FAS/FASL polymorphisms can predict lack of response to BCG immunotherapy and prevent the loss of valuable time before such alternative treatments as early cystectomy are initiated. PMID: 29453645 results suggest that miR-21 regulates the apoptosis of keloid fibroblasts via targeting FasL, and caspase-8 and the mitochondria-mediated apoptotic signaling pathway is involved in this process. PMID: 29527928 the detailed mechanisms of FasL-Fas necroptosis can help in understanding the processes of elimination of tumor cells that have blocked apoptosis signal transduction PMID: 30103900 Increased FASL expression is associated with dermatofibrosarcoma protuberans. PMID: 29509956 data demonstrated that FASL-844C/T SNP was substantially associated with idiopathic azoospermia, indicating that it might be a genetic predisposing factor of idiopathic azoospermia in the Western of Iran. PMID: 28942044 platelet-derived FasL has a role in apoptosis in stroke PMID: 27608763 The Fas-ligand SNP and TNF gene -308 SNP are associated with anti-TNF treatment response in Crohn's disease and may help select patients likely to benefit from therapy. PMID: 28785150 serum levels of soluble FAS ligand (sFASL) and interferon gamma (IFN-gamma) were analyzed and correlated with sFGL2 levels in Hepatitis C Virus-Infected Patients and Hepatocellular Carcinoma Patients. PMID: 28609212 Study shows for the first time that CD95L activates NHE1, which thereby enhances cell migration. Using a combination of inhibitors and site-directed mutagenesis, results subsequently demonstrate that this mechanism occurs through a modification of NHE1 cooperative response to intracellular protons and that it involves both the Akt and RhoA-dependent pathways. PMID: 27302366 These results suggest that the FasL -844T>C single nucleotide polymorphism is implicated in the susceptibility to hepatitis C virus in Egyptian patients and firstly report the involvement of TRAIL gene polymorphism in the risk of the disease. PMID: 28587866 Increased activation of B-cells is present following successful Tuberculosis treatment, and the expression of FASLG and IL5RA could potentially be utilized as a signature to monitor treatment response. PMID: 27682872 This study highlights a coordinated neurovascular development instructed by CNS macrophage-derived CD95L. PMID: 28514658 FasL -844C>T polymorphism plays a protective role against Head and Neck Cancer development in Asian population. PMID: 29419701 The Fas mRNA expression ratio was unchanged upon MTX treatment, but the FasL mRNA expression ratio was significantly higher in MTX-treated than nontreated polyps. In addition, the expression levels of the Fas and FasL proteins were significantly higher in polyps treated with both 10 and 100 muM MTX compared with nontreated polyps. PMID: 28468172 Results show that the FasL:Fas complex shares structural features with the FasL:DcR3 assembly and the glycosylation contributes to the activity of soluble FasL PMID: 27806260 FASLG c.-844TC genotype may be protective against familial mediterranean fever in the Turkish population. PMID: 28442396 The rs763110 TT genotype significantly increased the risk of cervical cancer compared with the CC/CT genotype. Patients carrying this genotype presented a lower cancerous FASL expression than that of the CC/CT genotypes. OCT1 was recruited to the FASL promoter region and regulated the FASL gene transcription by interacting with C/EBPbeta. PMID: 27790710 Inhibition of miR-149-5p can induce apoptosis in THP-1 cells. These inductive effects might be via targeting FASLG and activating FADD and caspases. PMID: 28013316 FasL gene polymorphism is associated with Hashimoto's thyroiditis. PMID: 27572459 There is a positive correlation of the serum level of sFasL ( Fas/FasL axis )with uptake index of parotid gland in our expectation. In addition, liver injury involvement in SS patients showed decreased level of sFasL. Furthermore, we here also observed that the protective cytokine IL-10 expression was positively correlated with sFasL expression PMID: 28326325 The results of this study did show an initial decrease in sCD95L, but this was followed by a steady increase above initially measured concentrations. Furthermore, we found that patients with clinically documented neurological remission showed higher sCD95L serum concentrations than patients without remission. PMID: 27089864 suppression of EP1 prevented RAMA-induced FasL suppression in CLT85 cells at both the mRNA and protein levels PMID: 26211005 In sprint-trained male athletes, FasL, miR-21, and miR-146a were measured cross-sectionally (n = 67, 18-90 yrs) and serum FasL, miR-21, and miR-146a and their aging-related associations with physical performance were assessed over a 10-year follow-up (n = 49, 50-90 yrs). PMID: 28127562 In women with endometriosis, immunostaining for Fas-Ligand in the eutopic endometrium was stronger in the epithelial cells of secretory phase, while the epithelial cells of endometriotic lesions showed a significantly stronger staining for Fas-Ligand independently from the menstrual phase PMID: 26156853 The study identified Fas ligand (FASLG) as the target of let-7e-5p, and FASLG knockdown increased the migration and tube formation of endothelial progenitor cell. PMID: 26826505 Case Reports: patients with autosomal recessive inheritance of ALPS-FASLG have a severe phenotype and a partial defect in activation-induced cell death in T- and B-cell lines. PMID: 26334989 No mutation or variation could be found in FASL in patients or controls. PMID: 26690594 FASL, granzyme B, and cytochrome c blood expression reflects breast cancer progression and response to therapy. (Review) PMID: 27117663 No association has been found between FASL promoter polymorphisms and predisposition to HIV infection. PMID: 26429326 FASL expression is an independent marker for earlier disease relapse and disease-specific death in oral squamous cell carcinoma. PMID: 26400345 These data indicate that Epstein-Barr virus exosomes derived from EBV-infected cells are taken up by non-infected cells and induce apoptosis via the extrinsic pathway, and that exosomes trigger apoptosis through the FasL pathway. PMID: 26467838 The expression of Ki67 and FasL is closely related to the occurrence and development of cervical carcinoma. PMID: 26345794 Data suggest Faim2/LFG (lifeguard protein) protects against FasL-/Fas ligand-induced apoptosis by down-regulating calcium release from endoplasmic reticulum in cortical neurons. PMID: 26582200 In patients with either Crohn's disease or ulcerative colitis, the extent of endothelial FasL expression was elevated in the submucosa and associated with an elevated number of lymphoid follicles. PMID: 26374830 Th1 cells express high level of FAS-ligand (FASL), which interacts with FAS and leads to caspases' cleavage and ultimately to cell death. PMID: 25950471 Fas Ligand Deficiency Impairs Tumor Immunity by Promoting an Accumulation of Monocytic Myeloid-Derived Suppressor Cells PMID: 26359460 FASL -844 T > C promoter single nucleotide polymorphism is associated with oral cancers. PMID: 25944167 Death induced by CD95R/L elimination (DICE) and CD95-mediated apoptosis have opposing roles in eliminating cancer stem cells (CSCs)and non-CSCs. PMID: 25366259 Membrane-bound FasL mediates platelets-induced apoptosis, whereas Bax/Bak signaling is not required but reinforces platelets-induced apoptosis. PMID: 26232171 DcR3 enhances ERK1/2 phosphorylation and opposes FasL signaling in pancreatic cancer cells PMID: 26102031 MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG. PMID: 25394756 FasL -844 CC combined with the Fas -1377 G allele is a protective factor against ESCC. PMID: 24473454 High Fas expression promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. PMID: 25333257 There was no correlation between TGF-beta1 levels and HBV load, but there is a positive correlation between sFas levels and HBV load. PMID: 25990938 data strongly indicate that the inhibition of ceramide conversion to complex sphingolipids by D609 is accompanied by an enhancement of FasL-induced caspase-dependent and -independent cell death in T lymphocytes. PMID: 22942738 during spontaneous miscarriages, the increased FasL-expressing population could be a part of an M1 phenotype participating in Fas/FasL-related apoptosis. PMID: 22942752 these findings provide novel experimental evidences supporting that VC or/and VE could reduce p,p'-DDT-induced cytotoxicity of HL-7702 cells via the ROS-mediated mitochondrial pathway and NF-kappaB/FasL pathway. PMID: 25464339 Fas ligand correlates with the documented degree of atrial apoptosis and atrial fibrosis in right atrial appendage tissue after cardiac surgery. PMID: 23790081 The T/T genotype and the T allele of the c.-844T>C polymorphism were associated with increased occurrence of keratoconus, while the C allele was associated with decreased keratoconus occurrence. PMID: 25169582

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.